$50-150 Billion Lifetime Revenue Opportunity for Apabetalone
Just for a reminder, I bring you back to a 2017 Corporate Update from Resverlogix, where the following statement is found:
Objective of today’s presentation is to provide high level commercial assumptions, scientific and clinical data, and primary market research that provide near future rationale for $50–$150 Billion lifetime revenue opportunity for apabetalone.
https://www.resverlogix.com/upload/event/18/c38685f1ce18/biopharm-america-2017.pdf
Sometimes a reminder is helpful.
J4P